Pindolol and the acceleration of the antidepressant response
Background: It has been suggested that treatment with selective serotonin reuptake inhibitors (SSRIs) in combination with pindolol, a partial agonist at the 5-HT 1A receptor, may produce a fast antidepressant response. However, inconsistent results have been obtained in clinical studies with combina...
Gespeichert in:
| Veröffentlicht in: | Journal of affective disorders 2003-08, Vol.75 (3), p.285-289 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 289 |
|---|---|
| container_issue | 3 |
| container_start_page | 285 |
| container_title | Journal of affective disorders |
| container_volume | 75 |
| creator | Plenge, Per Mellerup, Erling T. |
| description | Background: It has been suggested that treatment with selective serotonin reuptake inhibitors (SSRIs) in combination with pindolol, a partial agonist at the 5-HT
1A receptor, may produce a fast antidepressant response. However, inconsistent results have been obtained in clinical studies with combination of the two drugs. Some studies, most using paroxetine, show an acceleration of the antidepressant response, whereas studies with other SSRIs find no marked latency reduction.
Methods: The free SSRI concentration in patients either receiving the first dose, or in steady state treatment with the five different SSRIs citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline was estimated using pharmacokinetic data for the individual drugs.
Results: Due to differences between the drugs regarding protein binding, distribution volume and affinity for the 5-HT transporter (5-HTT), the 5-HT uptake inhibition obtained with clinically relevant doses differs markedly among the SSRIs.
Conclusions: A nearly complete blockade of the 5-HTT is obtained already after the first dose only with paroxetine, explaining why the latency reducing effect of pindolol preferentially is seen when pindolol is combined with paroxetine. |
| doi_str_mv | 10.1016/S0165-0327(02)00062-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73515328</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165032702000629</els_id><sourcerecordid>73515328</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-f405a1911d255924b0076a8ee72c2b1c234d81ef907610687ee051393a1a6f8c3</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhnNQ3HX1Jyi9KHqo5qNpGxBEFr9gQUE9h2wyxUg3qUlX8N-b7hY9esmEN89MhgehI4IvCCbl5Us6eI4Zrc4wPccYlzQXO2j6G0_Qfowfw4Oo8B6aEFrXWBRkiq6erTO-9W2mnMn6d8iU1tBCUL31LvPNNnO9NdAFiDFds1Q77yIcoN1GtREOxzpDb3e3r_OHfPF0_zi_WeSaCdLnTYG5IoIQQzkXtFhiXJWqBqiopkuiKStMTaARKSa4rCsAzAkTTBFVNrVmM3S6ndsF_7mG2MuVjWnLVjnw6ygrxglntE4g34I6-BgDNLILdqXCtyRYDqrkRpUcnEhM5UaVFKnvePxgvVyB-esaPSXgZARU1KptgnLaxj-Op0nDDjN0veUg6fiyEGTUFpwGYwPoXhpv_1nlB9BAhdo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73515328</pqid></control><display><type>article</type><title>Pindolol and the acceleration of the antidepressant response</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Plenge, Per ; Mellerup, Erling T.</creator><creatorcontrib>Plenge, Per ; Mellerup, Erling T.</creatorcontrib><description>Background: It has been suggested that treatment with selective serotonin reuptake inhibitors (SSRIs) in combination with pindolol, a partial agonist at the 5-HT
1A receptor, may produce a fast antidepressant response. However, inconsistent results have been obtained in clinical studies with combination of the two drugs. Some studies, most using paroxetine, show an acceleration of the antidepressant response, whereas studies with other SSRIs find no marked latency reduction.
Methods: The free SSRI concentration in patients either receiving the first dose, or in steady state treatment with the five different SSRIs citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline was estimated using pharmacokinetic data for the individual drugs.
Results: Due to differences between the drugs regarding protein binding, distribution volume and affinity for the 5-HT transporter (5-HTT), the 5-HT uptake inhibition obtained with clinically relevant doses differs markedly among the SSRIs.
Conclusions: A nearly complete blockade of the 5-HTT is obtained already after the first dose only with paroxetine, explaining why the latency reducing effect of pindolol preferentially is seen when pindolol is combined with paroxetine.</description><identifier>ISSN: 0165-0327</identifier><identifier>DOI: 10.1016/S0165-0327(02)00062-9</identifier><identifier>PMID: 12880941</identifier><identifier>CODEN: JADID7</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Acceleration ; Antidepressive ; Biological and medical sciences ; Depressive Disorder, Major - drug therapy ; Drug Administration Schedule ; Humans ; Hypothesis ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Pindolol ; Pindolol - antagonists & inhibitors ; Pindolol - therapeutic use ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Serotonin Antagonists - therapeutic use ; Serotonin Uptake Inhibitors - pharmacology ; Serotonin Uptake Inhibitors - therapeutic use ; SSRI ; Time Factors</subject><ispartof>Journal of affective disorders, 2003-08, Vol.75 (3), p.285-289</ispartof><rights>2002 Elsevier B.V.</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-f405a1911d255924b0076a8ee72c2b1c234d81ef907610687ee051393a1a6f8c3</citedby><cites>FETCH-LOGICAL-c391t-f405a1911d255924b0076a8ee72c2b1c234d81ef907610687ee051393a1a6f8c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0165-0327(02)00062-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15000515$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12880941$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Plenge, Per</creatorcontrib><creatorcontrib>Mellerup, Erling T.</creatorcontrib><title>Pindolol and the acceleration of the antidepressant response</title><title>Journal of affective disorders</title><addtitle>J Affect Disord</addtitle><description>Background: It has been suggested that treatment with selective serotonin reuptake inhibitors (SSRIs) in combination with pindolol, a partial agonist at the 5-HT
1A receptor, may produce a fast antidepressant response. However, inconsistent results have been obtained in clinical studies with combination of the two drugs. Some studies, most using paroxetine, show an acceleration of the antidepressant response, whereas studies with other SSRIs find no marked latency reduction.
Methods: The free SSRI concentration in patients either receiving the first dose, or in steady state treatment with the five different SSRIs citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline was estimated using pharmacokinetic data for the individual drugs.
Results: Due to differences between the drugs regarding protein binding, distribution volume and affinity for the 5-HT transporter (5-HTT), the 5-HT uptake inhibition obtained with clinically relevant doses differs markedly among the SSRIs.
Conclusions: A nearly complete blockade of the 5-HTT is obtained already after the first dose only with paroxetine, explaining why the latency reducing effect of pindolol preferentially is seen when pindolol is combined with paroxetine.</description><subject>Acceleration</subject><subject>Antidepressive</subject><subject>Biological and medical sciences</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Drug Administration Schedule</subject><subject>Humans</subject><subject>Hypothesis</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pindolol</subject><subject>Pindolol - antagonists & inhibitors</subject><subject>Pindolol - therapeutic use</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Serotonin Antagonists - therapeutic use</subject><subject>Serotonin Uptake Inhibitors - pharmacology</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>SSRI</subject><subject>Time Factors</subject><issn>0165-0327</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAQhnNQ3HX1Jyi9KHqo5qNpGxBEFr9gQUE9h2wyxUg3qUlX8N-b7hY9esmEN89MhgehI4IvCCbl5Us6eI4Zrc4wPccYlzQXO2j6G0_Qfowfw4Oo8B6aEFrXWBRkiq6erTO-9W2mnMn6d8iU1tBCUL31LvPNNnO9NdAFiDFds1Q77yIcoN1GtREOxzpDb3e3r_OHfPF0_zi_WeSaCdLnTYG5IoIQQzkXtFhiXJWqBqiopkuiKStMTaARKSa4rCsAzAkTTBFVNrVmM3S6ndsF_7mG2MuVjWnLVjnw6ygrxglntE4g34I6-BgDNLILdqXCtyRYDqrkRpUcnEhM5UaVFKnvePxgvVyB-esaPSXgZARU1KptgnLaxj-Op0nDDjN0veUg6fiyEGTUFpwGYwPoXhpv_1nlB9BAhdo</recordid><startdate>20030801</startdate><enddate>20030801</enddate><creator>Plenge, Per</creator><creator>Mellerup, Erling T.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030801</creationdate><title>Pindolol and the acceleration of the antidepressant response</title><author>Plenge, Per ; Mellerup, Erling T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-f405a1911d255924b0076a8ee72c2b1c234d81ef907610687ee051393a1a6f8c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Acceleration</topic><topic>Antidepressive</topic><topic>Biological and medical sciences</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Drug Administration Schedule</topic><topic>Humans</topic><topic>Hypothesis</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pindolol</topic><topic>Pindolol - antagonists & inhibitors</topic><topic>Pindolol - therapeutic use</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Serotonin Antagonists - therapeutic use</topic><topic>Serotonin Uptake Inhibitors - pharmacology</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>SSRI</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Plenge, Per</creatorcontrib><creatorcontrib>Mellerup, Erling T.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of affective disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Plenge, Per</au><au>Mellerup, Erling T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pindolol and the acceleration of the antidepressant response</atitle><jtitle>Journal of affective disorders</jtitle><addtitle>J Affect Disord</addtitle><date>2003-08-01</date><risdate>2003</risdate><volume>75</volume><issue>3</issue><spage>285</spage><epage>289</epage><pages>285-289</pages><issn>0165-0327</issn><coden>JADID7</coden><abstract>Background: It has been suggested that treatment with selective serotonin reuptake inhibitors (SSRIs) in combination with pindolol, a partial agonist at the 5-HT
1A receptor, may produce a fast antidepressant response. However, inconsistent results have been obtained in clinical studies with combination of the two drugs. Some studies, most using paroxetine, show an acceleration of the antidepressant response, whereas studies with other SSRIs find no marked latency reduction.
Methods: The free SSRI concentration in patients either receiving the first dose, or in steady state treatment with the five different SSRIs citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline was estimated using pharmacokinetic data for the individual drugs.
Results: Due to differences between the drugs regarding protein binding, distribution volume and affinity for the 5-HT transporter (5-HTT), the 5-HT uptake inhibition obtained with clinically relevant doses differs markedly among the SSRIs.
Conclusions: A nearly complete blockade of the 5-HTT is obtained already after the first dose only with paroxetine, explaining why the latency reducing effect of pindolol preferentially is seen when pindolol is combined with paroxetine.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>12880941</pmid><doi>10.1016/S0165-0327(02)00062-9</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-0327 |
| ispartof | Journal of affective disorders, 2003-08, Vol.75 (3), p.285-289 |
| issn | 0165-0327 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73515328 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Acceleration Antidepressive Biological and medical sciences Depressive Disorder, Major - drug therapy Drug Administration Schedule Humans Hypothesis Medical sciences Neuropharmacology Pharmacology. Drug treatments Pindolol Pindolol - antagonists & inhibitors Pindolol - therapeutic use Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Serotonin Antagonists - therapeutic use Serotonin Uptake Inhibitors - pharmacology Serotonin Uptake Inhibitors - therapeutic use SSRI Time Factors |
| title | Pindolol and the acceleration of the antidepressant response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A13%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pindolol%20and%20the%20acceleration%20of%20the%20antidepressant%20response&rft.jtitle=Journal%20of%20affective%20disorders&rft.au=Plenge,%20Per&rft.date=2003-08-01&rft.volume=75&rft.issue=3&rft.spage=285&rft.epage=289&rft.pages=285-289&rft.issn=0165-0327&rft.coden=JADID7&rft_id=info:doi/10.1016/S0165-0327(02)00062-9&rft_dat=%3Cproquest_cross%3E73515328%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73515328&rft_id=info:pmid/12880941&rft_els_id=S0165032702000629&rfr_iscdi=true |